Robert Lechleider Sells 55,000 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) insider Robert Lechleider sold 55,000 shares of the business’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $22.62, for a total value of $1,244,100.00. Following the transaction, the insider directly owned 15,805 shares of the company’s stock, valued at $357,509.10. This trade represents a 77.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Robert Lechleider also recently made the following trade(s):

• On Thursday, June 25th, Robert Lechleider sold 55,000 shares of Immunome stock. The shares were sold at an average price of $19.85, for a total value of $1,091,750.00.

Immunome Stock Down 1.6%

Immunome stock opened at $24.01 on Thursday. The stock has a market cap of $2.72 billion, a PE ratio of -10.09 and a beta of 2.07. Immunome, Inc. has a 12-month low of $7.96 and a 12-month high of $27.65. The business’s 50-day moving average price is $21.00 and its two-hundred day moving average price is $21.86.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.12. As a group, analysts expect that Immunome, Inc. will post -2.06 earnings per share for the current year.

Analyst Ratings Changes

IMNM has been the subject of a number of recent research reports. Wedbush reaffirmed an “outperform” rating and issued a $31.00 target price on shares of Immunome in a report on Friday, June 12th. Barclays initiated coverage on Immunome in a research note on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price objective for the company. Leerink Partners reduced their target price on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a report on Friday, May 15th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Immunome in a research note on Wednesday, May 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a report on Tuesday, April 21st. Twelve research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $33.17.

Institutional Trading of Immunome

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IMNM. Bank of America Corp DE lifted its position in shares of Immunome by 285.6% in the 1st quarter. Bank of America Corp DE now owns 781,607 shares of the company’s stock worth $17,094,000 after purchasing an additional 578,890 shares during the period. Edgestream Partners L.P. bought a new position in Immunome during the first quarter worth $1,310,000. California State Teachers Retirement System raised its position in shares of Immunome by 66.3% in the 1st quarter. California State Teachers Retirement System now owns 111,444 shares of the company’s stock worth $2,437,000 after acquiring an additional 44,432 shares in the last quarter. Quantinno Capital Management LP bought a new stake in Immunome in the first quarter worth approximately $222,000. Finally, Aristotle Atlantic Partners LLC acquired a new position in Immunome in the first quarter valued at approximately $2,734,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.